CLGN to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI”
Company is rebranding to optical computing focus with a $5 billion TAM deal secured and moving to Nasdaq, positioning for significant growth as a cutting-edge tech company.
| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | 3 | 3 | 1 | 33% | -1.4% | -2.6% |
| 3d | 3 | 3 | 1 | 33% | -2.8% | -6.4% |
| 1w | 2 | 2 | 1 | 50% | +7.1% | +7.1% |
| 1m | 2 | 2 | 2 | 100% | +39.4% | +39.4% |
| 3m | 2 | 2 | 2 | 100% | +72.0% | +72.0% |
| 6m | 2 | 2 | 2 | 100% | +140.7% | +140.7% |
| 1y | 1 | 1 | 1 | 100% | +236.5% | +236.5% |
Past performance does not predict future results. Informational only, not investment advice.
Company is rebranding to optical computing focus with a $5 billion TAM deal secured and moving to Nasdaq, positioning for significant growth as a cutting-edge tech company.
Alpha Tau's revolutionary cancer treatment achieved first-ever successful GBM (glioblastoma) patient treatment with FDA Breakthrough Device Designation. The company's platform has proven efficacy across multiple solid tumors and holds ~$350M market cap with significant upside potential as awareness grows and additional catalysts (e.g., PMDA approval in Japan) materialize.
DRTS is developing a revolutionary cancer treatment approaching PMDA approval in Japan before year-end, with both CEO and CFO's presence suggesting serious commercialization progress. The company has FDA breakthrough designation, all necessary capital, strong phase 2/3 results, and a tiny market cap in a massive market with virtually no retail awareness, positioning it as a multi-bagger opportunity.
End of results.